Revolu-zoldonrasib vs placebo for KRAS G12D pancreatic cancer (RMC-9805-305) - Clinical Trial

or email

gi-oncology-cru@dm.duke.edu

¿Cuál es el Propósito de este estudio?

Participants will take a study pill every day and receive chemotherapy infusions every 1 to 2 weeks. They will also have tumor biopsies, provide blood and urine samples, and undergo regular CT or MRI scans to monitor their cancer during the study.

¿Cuál es la Condición que se está estudiando?

Cáncer pancreático

¿Quién puede participar en el Estudio?

Participants may be able to join if they are adults with pancreatic adenocarcinoma that has spread to other parts of the body, contains a KRAS G12D mutation, and has not been treated before.

Grupo etario

Adultos

¿Qué Implica?

This study is testing whether the study drug zoldonrasib can help treat cancers with a specific genetic change called KRAS G12D. Researchers want to learn how well the drug works and how safe it is when used with chemotherapy.

Detalles del Estudio

Título Completo

[RMC-9805-305] A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

Investigador Principal